What is FECO and how is it different from CBD oil?

FECO (Full Extract Cannabis Oil) is a whole-plant cannabis extract containing the full spectrum of cannabinoids including high-THC content (typically 60–90% THC), CBD, CBN, CBG, and terpenes. It is extracted using ethanol to preserve this profile. CBD oil, by contrast, is derived from hemp, contains less than 0.3% THC, and produces no psychoactive effects. FECO is also known as RSO (Rick Simpson Oil) and is used in alternative cancer protocols.

What does the research say about cannabinoids and cancer?

Preclinical research (cell studies and animal models) shows cannabinoids can inhibit tumor growth via multiple mechanisms: CB1/CB2 receptor activation leading to ceramide accumulation, ER stress, autophagy, and apoptosis in cancer cells. Velasco et al. (2012, Nature Reviews Cancer) reviewed these mechanisms extensively. Munson et al. (1975) were the first to document THC inhibiting Lewis lung adenocarcinoma in mice. However, as of 2026, no completed Phase III randomized controlled trials in humans have established FECO as a cancer treatment. Evidence remains preclinical.

What is the entourage effect?

The entourage effect is the theory that the full spectrum of cannabinoids, terpenes, and other compounds in whole-plant cannabis extracts work synergistically, producing effects greater than any single isolated cannabinoid. This is the primary rationale for preferring FECO over isolated CBD or THC. While supported by preclinical evidence and some expert consensus, robust human RCT data specifically comparing full-spectrum to isolates for cancer outcomes does not yet exist.

FECO/RSO is federally Schedule I in the United States due to its high THC content, making it illegal under federal law regardless of state law. It is legal for medical or recreational use in several US states where cannabis is legal. Internationally, legal status varies widely — it is legal in some jurisdictions (Canada, Netherlands, Germany post-2024) and strictly prohibited in others. Always verify local laws before purchasing, possessing, or using FECO.

What are the main safety concerns with FECO?

FECO contains 60–90% THC, making it highly psychoactive. Key safety concerns include: significant cognitive impairment and coordination issues especially at high doses; tolerance development requiring dose escalation; drug interactions through CYP3A4 and CYP2C9 enzymes (relevant for chemotherapy drugs, blood thinners, and other medications); legal risks in many jurisdictions; and quality control concerns with unregulated products including contamination or inconsistent potency. Always consult a healthcare provider before use.

What equipment is used for FECO dosing?

FECO is typically a thick, viscous oil that is difficult to dose accurately. Common equipment includes oral glass syringes (1ml or 5ml) for measuring precise volumes, which allows gradual titration from micro-doses (a grain of rice size, roughly 5–10mg THC) up to higher therapeutic doses. Some users fill empty capsules using capsule filling machines to avoid the taste and make dosing more convenient.

FECO (Full Extract Cannabis Oil) Research Guide: RSO, Cannabinoids & Cancer

Overview

What Is FECO?

Full Extract Cannabis Oil is a concentrated whole-plant cannabis extract made using ethanol solvent. Unlike isolates or distillates, FECO retains the complete cannabinoid and terpene profile — which proponents believe creates synergistic "entourage" effects not achievable with isolated compounds.

What It Contains

Full Cannabinoid & Terpene Profile

FECO preserves the complete chemical complexity of cannabis — all major and minor cannabinoids plus terpenes that may be lost in refined extracts.

THC (60–90%) CBD CBN CBG CBC THCA Terpenes Flavonoids

Also Known As

RSO — Rick Simpson Oil

Rick Simpson popularized this extract type after claiming to treat his own skin cancer with it in 2003. His protocol involved high-dose THC oil taken orally over 90 days. FECO is functionally identical to RSO — the names are used interchangeably, though RSO sometimes refers to a specific dark, tar-like oil while FECO can range in consistency.

Extraction

Ethanol-Based Whole Plant

Ethanol is used as the solvent to strip all soluble compounds from the plant material, then evaporated off. This preserves polar and non-polar compounds alike — including chlorophyll, which gives FECO its characteristic dark green/black color. Supercritical CO₂ can also be used but may lose some terpenes.

Context

Joe Tippens Protocol

FECO/RSO gained renewed attention as part of the Joe Tippens Protocol — a combination regimen involving fenbendazole, vitamin E succinate, CBD oil, and FECO, documented after Tippens' widely-publicized stage 4 lung cancer remission. Whether any single component or the combination drove outcomes remains unknown. See also: Fenbendazole Guide.

Mechanisms of Action

How Cannabinoids Act on Cancer Cells

Preclinical research has identified several molecular pathways through which cannabinoids — particularly THC and CBD — may affect tumor cell biology. These are well-characterized in vitro and in animal models; human translation remains an open question.

🔗

CB1 & CB2 Receptor Activation

THC binds to CB1 receptors (primarily CNS) and CB2 receptors (immune cells, peripheral tissues). CB2 receptor activation in tumor cells has been particularly associated with anti-proliferative effects. Receptor engagement initiates downstream signaling cascades including Akt/mTOR pathway inhibition and ceramide accumulation. CB2 agonism may also modulate the tumor microenvironment via immune cell signaling.

🧪

Ceramide Pathway & ER Stress

The ceramide pathway is the most studied molecular mechanism of cannabinoid-induced cancer cell death. CB receptor activation stimulates ceramide synthesis via sphingomyelinase. Ceramide accumulation triggers endoplasmic reticulum (ER) stress, activating the unfolded protein response. This cascade promotes both autophagy (cellular self-digestion) and apoptosis (programmed cell death) in tumor cells, without similar effects in normal cells.

🌿

Entourage Effect

The entourage effect theory holds that minor cannabinoids (CBN, CBG, CBC) and terpenes (myrcene, limonene, β-caryophyllene) potentiate or modulate the effects of THC and CBD synergistically. β-caryophyllene is itself a CB2 agonist. Some terpenes may increase cannabinoid bioavailability by enhancing cell membrane permeability. This is the primary rationale for preferring whole-plant FECO over isolated THC or CBD.

Cannabinoid → Cancer Cell Death Pathway

THC/CBD Binding
CB1 & CB2 Receptors

→

Ceramide Accumulation
Sphingomyelinase activation

→

ER Stress Response
UPR activation

→

Autophagy
Beclin-1 pathway

→

Apoptosis
Caspase cascade

Additionally: anti-angiogenesis (VEGF reduction), inhibition of tumor cell migration, and immune modulation via CB2 on tumor-infiltrating lymphocytes.

Comparison

FECO vs CBD Oil — Key Differences

These products are fundamentally different in composition, legal status, and intended use. Understanding the distinction is critical before researching either.

Property	FECO / RSO	CBD Oil (Hemp)
THC Content	60–90% THC	<0.3% THC (federally legal threshold)
Psychoactive	Yes — significantly	No
Spectrum	Full-spectrum: all cannabinoids + terpenes	Varies: full-spectrum, broad-spectrum, or isolate
Source Plant	Cannabis (marijuana) — high-THC cultivars	Hemp — low-THC industrial cultivars
Federal Legal (US)	Illegal — Schedule I	Legal (2018 Farm Bill)
Entourage Effect	Full profile	Partial (no THC)
Dosing	Microgram titration required; start at rice-grain dose	Standard drops/capsules; wide safety margin
Chemo Side Effect Relief	Strong antiemetic, analgesic, appetite stimulant	Mild antiemetic; less potent for nausea/pain
Tolerance	Develops with chronic use	Minimal tolerance reported
Primary Cancer Research	Preclinical animal models; some Phase I/II trials	Preclinical; fewer human trials for cancer

Research Evidence

What the Science Shows

Evidence ranges from robust preclinical data to limited human trials. Evidence levels are rated relative to each category's ideal standard.

Preclinical Anti-Tumor Evidence

Velasco et al. 2012 (Nature Reviews Cancer) — Multiple tumor types, multiple mechanisms confirmed in cell & animal models

Strong

THC Lung Adenocarcinoma Inhibition (Mouse)

Munson et al. 1975 — First published study; THC inhibited Lewis lung adenocarcinoma growth in mice

Historical

THC + Temozolomide Synergy (Glioblastoma, Mouse)

Torres et al. 2011 — THC combined with TMZ showed synergistic tumor reduction in GBM xenografts

Preclinical

Nabiximols Phase II GBM Trial (Human)

GW Pharmaceuticals — THC:CBD (Sativex) showed improved 1-year survival vs placebo in recurrent GBM (preliminary)

Phase II Only

Phase III Human RCT Evidence for Cancer

No completed Phase III RCTs have established FECO/cannabinoids as a cancer treatment as of 2026

None

Supportive Care Evidence (Antiemetic, Analgesic)

FDA-approved dronabinol (synthetic THC) for chemo-induced nausea; cannabinoids well-established for symptom management

Strong

The Evidence Gap: There is a significant disconnect between robust preclinical anti-tumor data and confirmed human efficacy. Many compounds that kill cancer cells in dishes or mice fail in human trials due to bioavailability, dosing, tumor microenvironment differences, and other factors. The existing human data (Phase I/II) is preliminary and does not establish FECO as a cancer treatment. Supportive care use (nausea, pain, appetite) has much stronger human evidence.

Safety Profile

Risks & Considerations

FECO contains 60–90% THC. High-dose THC presents significant psychoactive and practical risks that must be understood before use. Drug interactions are particularly relevant for cancer patients on chemotherapy.

⚠️ Primary Risks

Severe psychoactive impairment — cognitive, coordination, and judgment effects at high THC doses
Anxiety, paranoia, and psychosis risk — particularly in naive users and at high doses
CYP3A4 & CYP2C9 enzyme inhibition — affects metabolism of many cancer drugs, blood thinners, and antiretrovirals
Cardiovascular effects — transient tachycardia and blood pressure changes
Legal risk — federally Schedule I; possession can result in criminal prosecution

⚡ Ongoing Concerns

Tolerance development — efficacy may decrease with chronic high-dose use
Cannabis Use Disorder — dependence possible with prolonged use
Quality control — unregulated products may contain pesticides, solvents, or incorrect potency labeling
Drug-drug interactions — always disclose to oncologist if using alongside chemotherapy
Memory and cognition — long-term heavy THC use associated with cognitive effects

💊 Drug Interactions (CYP)

CYP3A4 substrate drugs: paclitaxel, docetaxel, vincristine, tamoxifen — levels may increase
CYP2C9 substrates: warfarin (significant bleeding risk), phenytoin, NSAIDs
CNS depressants: alcohol, benzodiazepines — additive sedation
Immunosuppressants: cyclosporine — narrow therapeutic window affected

🚫 Absolute Cautions

Personal or family history of psychosis or schizophrenia — THC is a known trigger
Pregnancy and breastfeeding — associated with adverse fetal outcomes
Operating heavy machinery or driving — impaired reaction time and judgment
Pediatric use without specialist oversight — significant developmental risk

Legal Status

Where Is FECO Legal?

Legal status is highly jurisdiction-dependent and changes frequently. The information below is general and not legal advice. Always verify current laws in your specific location.

🇺🇸

United States (Federal)

Schedule I

Illegal federally. Legal in 24+ states for adult use; medical only in others. State law does not override federal enforcement risk.

🇨🇦

Canada

Legal

Federally legal since 2018 Cannabis Act. Cannabis extracts legal with purchase limits. Requires licensed retailer.

🇩🇪

Germany

Partial Legal

Cannabis legalized April 2024 for adults (limited personal possession). Medical cannabis available via prescription since 2017.

🌍

Rest of World

Varies

Ranges from full prohibition to decriminalization to medical programs. Netherlands, Uruguay, Thailand have varying degrees of legal access.

Important: Even in US states where cannabis is legal, FECO products from dispensaries may vary widely in cannabinoid ratios and quality. Only purchase from licensed, lab-tested sources. Bringing cannabis across state lines remains a federal crime even between two legal states.

FAQ

Frequently Asked Questions

Common questions about FECO, RSO, and cannabinoid research.

FECO (Full Extract Cannabis Oil) is a whole-plant cannabis extract with high THC content — typically 60–90% — along with CBD, CBN, CBG, and the plant's full terpene profile. It is extracted using ethanol solvent and is psychoactive. CBD oil is derived from hemp, contains less than 0.3% THC by law, and produces no intoxicating effects. FECO is federally Schedule I in the US; CBD oil derived from hemp is federally legal. FECO is also known as RSO (Rick Simpson Oil) and is the oil used in alternative cancer protocols like the Joe Tippens Protocol.

Preclinical research is genuinely compelling. Velasco et al. (2012, Nature Reviews Cancer) documented multiple mechanisms by which cannabinoids inhibit tumor growth in cell lines and animal models — apoptosis induction via ceramide accumulation, autophagy, anti-angiogenesis, and immune modulation. Munson et al. (1975) were the first to show THC inhibiting Lewis lung adenocarcinoma in mice. Torres et al. (2011) showed synergy between THC and temozolomide in glioblastoma mouse models. A preliminary Phase II trial by GW Pharmaceuticals showed improved survival in recurrent GBM with nabiximols. However, as of 2026, no completed Phase III randomized controlled trials have established cannabinoids as a human cancer treatment. The preclinical-to-clinical translation has not been proven.

The entourage effect describes the proposed synergy between cannabinoids, terpenes, and other cannabis compounds — the idea that the whole is greater than the sum of its parts. It's the primary rationale for using full-spectrum FECO over isolated THC or CBD. There is preclinical evidence supporting this: β-caryophyllene (a terpene) is itself a CB2 agonist; some terpenes appear to modulate CB receptor binding; minor cannabinoids like CBG and CBN have independent pharmacological activity. However, robust human clinical trial data specifically comparing full-spectrum extracts to isolates for cancer outcomes does not exist. The entourage effect is scientifically plausible and has preclinical support, but has not been definitively proven in controlled human studies.

FECO is federally Schedule I in the United States because of its high THC content. This means it is illegal under federal law regardless of your state's cannabis laws. It is legal for adult or medical use in many US states, Canada, Germany (since 2024), and several other jurisdictions — but remains illegal in many countries. You cannot legally transport FECO across international borders, across US state lines (even between two legal states), or into federal property. Penalties vary enormously by jurisdiction. Always verify your specific local laws before purchasing, possessing, or using FECO.

The most clinically significant interactions involve CYP enzyme inhibition. THC and CBD inhibit CYP3A4 and CYP2C9, which metabolize a wide range of medications. For cancer patients this is particularly important: paclitaxel, docetaxel, vincristine, and tamoxifen are all CYP3A4 substrates — FECO use could increase their blood levels and toxicity. Warfarin (CYP2C9) interaction can increase bleeding risk significantly. CNS depressants including benzodiazepines and opioids will have additive sedation. Always disclose FECO use to your oncologist or prescribing physician before starting — this is non-negotiable.

FECO is a potent extract and must be titrated carefully. The conventional starting protocol begins with a dose the size of a grain of rice — approximately 5–10mg of THC — taken orally once or twice daily. The dose is increased slowly over 3–5 weeks as tolerance develops. Rick Simpson's original protocol targeted 1 gram of oil per day (500–900mg THC) over 90 days, but this is an extreme dose that causes intense psychoactive effects and is difficult for most people to tolerate. Most users find much lower doses practical. Use glass oral syringes (1mL graduated) to measure precise volumes. Some people fill empty capsules using a capsule filling machine for convenience and taste masking. Working with a cannabis-knowledgeable healthcare provider is strongly recommended.

Joe Tippens was diagnosed with small-cell lung cancer in 2016 and given 3 months to live. He began a self-directed protocol including fenbendazole (an anthelmintic), vitamin E succinate, CBD oil, and FECO. His cancer went into complete remission within months, documented by his oncologist. While his case attracted enormous attention, it remains a single anecdotal case — not a clinical trial. It's impossible to determine which component(s) were responsible for his outcome, whether his diagnosis was correct, or whether spontaneous remission occurred. The Tippens Protocol has driven significant interest in both fenbendazole and cannabinoids for cancer. See our Fenbendazole Research Guide for more.

FECO: Full Extract Cannabis Oil Research Guide